BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy

BACKGROUND: The impact of BRAF tumor mutations on the natural course of disease of melanoma patients is controversial. PATIENTS AND METHODS: We analyzed the mutational status and overall survival of 215 patients receiving treatment with dacarbazine or temozolomide. All patients who started first-lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Meckbach, Diana, Keim, Ulrike, Richter, Sabina, Leiter, Ulrike, Eigentler, Thomas K., Bauer, Jürgen, Pflugfelder, Annette, Büttner, Petra, Garbe, Claus, Weide, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930670/
https://www.ncbi.nlm.nih.gov/pubmed/24586605
http://dx.doi.org/10.1371/journal.pone.0089218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930670/
https://www.ncbi.nlm.nih.gov/pubmed/24586605
http://dx.doi.org/10.1371/journal.pone.0089218

Ejemplares similares